Molecular mechanism of lenvatinib resistance in hepatocellular carcinoma
Journal Title: Journal of Clinical Hepatology - Year 2024, Vol 40, Issue 12
Abstract
Hepatocellular carcinoma is the most common malignancy of the liver and poses serious health burdens on China and the whole world. However， most patients with hepatocellular carcinoma are already in the advanced stage at the time of diagnosis， with fewer opportunities for surgery and limited treatment options. In recent years， the advances in molecular targeted therapies have brought new hope for patients with advanced hepatocellular carcinoma. Among these therapies， lenvatinib is the second first-line drug after sorafenib approved by the US Food and Drug Administration for the treatment of advanced hepatocellular carcinoma， and it has attracted widespread attention for its powerful anti-tumor properties. However， the efficacy of lenvatinib is severely limited by its drug resistance. This article reviews the research advances in the molecular mechanisms of lenvatinib resistance in hepatocellular carcinoma and discusses possible ways to improve the efficacy of lenvatinib， so as to improve its efficacy.
Authors and Affiliations
Xiaomeng YAO, Keke SUN, Yunkai LIN, Hui WANG, Liwei DONG, Lei CHEN, Heping HU
Keywords
Related Articles
- EP ID EP753937
- DOI 10.12449/JCH241225
- Views 17
- Downloads 0
Guideline for diagnosis and treatment of liver failure （2024 version）
Liver failure is a severe clinical syndrome of liver disease with an extremely high mortality rate. Over the years， scholars worldwide have continuously investigated various aspects of liver failure， including its defi...
Role of neuroimmune communication via the gut-brain axis in the pathogenesis of hepatic encephalopathy
Hepatic encephalopathy （HE） is a common severe liver disease syndrome in clinical practice and is one of the critical and severe diseases in internal medicine， and more than half of liver failure patients diagnosed wi...
Research advances in traditional Chinese medicine syndromes of fatty liver disease
Fatty liver disease can be classified into alcoholic fatty liver disease and nonalcoholic fatty liver disease based on etiology， and it has become the most important liver disease worldwide. Due to the differences in th...
Risk factors for liver cancer in chronic hepatitis B patients and construction of a nomogram prediction model
[Objective] To investigate the risk factors for liver cancer in patients with chronic hepatitis B （CHB） in the Qidong Chronic Hepatitis B cohort， and to construct a nomogram model for predicting the risk of liver canc...
Advances and challenges in eliminating mother-to-child transmission of hepatitis B virus worldwide
At present， there are policies for hepatitis B testing in 89.8% of countries and regions around the world. In 2022， the global hepatitis B vaccine birth dose coverage reached 45%， while the third-dose coverage reached...